Press Release: Journey Clinical Launches Nation’s Largest Directory of Psychedelic Psychotherapists Following Historic Federal Executive Order | Cannabis Law Report | How to order Skittles Moonrock online

Learn how to buy CBD Oil online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

Comprehensive therapist network spanning 26 states positions platform to deliver emerging psychedelic treatments—including psilocybin therapy—at scale upon FDA approval

NEW YORK, NY – April 28, 2026 – Journey Clinical, the largest psychedelic-assisted psychotherapy platform in the US, today announced the public launch of the nation’s most comprehensive directory of licensed psychedelic psychotherapists. The announcement comes amid rapid federal action: one week after a landmark Executive Order expanded research and access to psychedelics for serious mental illness, and as the FDA awarded priority review vouchers to three programs, including COMP360 psilocybin therapy from Compass Pathways, Journey Clinical’s research collaborator.

The directory features licensed mental health professionals across 26 states trained in psychedelic-assisted care and experienced with the preparation-dosing-integration model. Since its founding in 2021, Journey Clinical has built the provider network and patient care system necessary to deliver psychedelic therapies responsibly and at scale when FDA approval arrives.

“This executive order signaled that the country is catching up to what our therapist community has known for years: that psychedelic-assisted therapy works, and that the platform to deliver it at scale needs to exist before approval arrives,” said Myriam Barthes, Co-Founder & CEO of Journey Clinical.

“Now, with the FDA awarding a priority review voucher to our research partner Compass Pathways, that moment of approval could arrive much sooner than many anticipated. At Journey Clinical, we have spent five years building the pathway—the therapist network, the medical care model, the insurance coverage. We are ready, willing, and able to bring these treatments to patients the moment FDA approval is received.”

Americans, Choose Your Psychedelic Therapist Today

The Executive Order directs the FDA and DEA to create pathways for eligible patients to access investigational psychedelic compounds under the Right to Try Act, allocates $50 million through ARPA-H to match state investments in psychedelic research, and directs the Attorney General to initiate scheduling reviews for substances that complete Phase 3 trials. Journey Clinical’s platform is already in place:

• Nationwide therapist network: Licensed therapists across 26 states trained in psychedelic-assisted care
• Collaborative care model: Medical team coordinating with therapists to ensure safe, structured, personalized treatment
• Insurance coverage: In-network with major insurance plans, with many patients receiving reimbursement for appointments
• Research partnerships: Active collaboration with Compass Pathways to develop scalable delivery and training models for COMP360 psilocybin treatment (currently in Phase 3 trials with FDA Breakthrough Therapy designation)

The urgency is clear. Over 14 million American adults live with serious mental illness, and approximately 8 million are on prescription medication—many without adequate relief. For more than 20 years, there have been over 6,000 veteran suicides per year, at a rate more than twice that of the non-veteran adult population.

“Approving a drug is not enough if there aren’t enough trained therapists to administer it, medical providers to prescribe and monitor it, platforms to coordinate care at scale, and insurance coverage to make it affordable,” Barthes said. “Journey Clinical exists to close all of those gaps—and we already have.”

What’s Available Now

For patients seeking psychedelic-assisted therapy today, ketamine remains the only legally available option in the U.S. Journey Clinical’s network continues to offer KAP to patients across 26 states. Patients and therapists can explore the directory at my.journeyclinical.com/directory.

“The promise of psychedelic-assisted therapy will only be realized if the ecosystem around it is built with the same rigor and care as the science itself,” Barthes added. “We are committed to doing that work when approval arrives, and every day between now and then, and every day after. The patients waiting for these treatments deserve nothing less.”

About Journey Clinical

Journey Clinical is the largest platform for FDA-approved psychedelic-assisted psychotherapy, expanding access to the next generation of evidence-based mental health treatments. Grounded in rigorous clinical practice, the platform helps people find licensed psychedelic therapists across 26 states who are equipped with the resources to deliver care safely and confidently, including a dedicated medical team, insurance pathways, clinical education, and a collaborative professional community.

Through an integrated model of psychotherapy and psychiatry, Journey Clinical helps patients address the root causes of depression and anxiety with insurance-covered ketamine-assisted psychotherapy (KAP), Spravato®, and comprehensive medication management, resulting in improved clinical outcomes for 87% of patients. Since launching in 2021, the company has facilitated more than 1 million hours of KAP in partnership with a nationwide network of over 3,000 therapists.